Improved survival after offspring donor transplant compared with older aged‐matched siblings for older leukaemia patients

摘要

Summary Donor selection for older leukaemia patients undergoing haematopoietic cell transplant (HCT) is not well defined: outcomes might be improved with a younger offspring donor rather than an older human leukocyte antigen (HLA)‐matched sibling donor (MSD). We extended our multicentre dataset. A total of 185 acute leukaemia patients (≥?50?years) transplanted in first complete remission who received HCT from offspring ( n ?=?62) or MSD ( n ?=?123) were included. A 1:1 ratio matched‐pair analysis was performed. We were able to match 54 offspring with 54 MSD patients. Outcomes were compared between the two matched‐pair groups. The cumulative incidence of grade II/IV acute graft‐versus‐host disease (GVHD) (26% vs. 35%; P ?=?0·23) and chronic GVHD (37% vs. 24%; P ?=?0·19) was comparable between groups (MSD vs. offspring). The lower three‐year transplant‐related mortality (9% vs. 26%; P ?=?0·023) and relapse incidence (6% vs. 17%; P ?=?0·066) resulted in higher overall survival (85% vs. 58%; P ?=?0·003) and leukaemia‐free survival (LFS) (85% vs. 56%; P ?=?0·001) in offspring HCT compared with that in MSD HCT. These data might favour a young offspring over an older MSD in patients 50?years. The current analyses confirm that non‐HLA donor characteristics, such as kinship and donor age, rather than HLA disparity, predominantly influence survival in older acute leukaemia patients.